MENLO PARK, Calif., Dec. 7, 2016 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology market, will share research at the Antibacterial Discovery and Development Summit in Boston that suggests topical delivery of minocycline may be effective for the treatment of acne because, in topical form, minocycline may fight P. acnes-induced local inflammation.
The study, which for the first time evaluates topical minocycline efficacy in a murine model of acne, suggested that a topical formulation effectively delivered minocycline into the skin and improved efficacy against P. acnes. Results will be showcased in a poster Thursday.
Title: "Therapeutic Effects of a Topical Minocycline in an Inflammatory Skin Disorder Animal Model,"
Presenter: Usha Nagavarapu, Ph.D.
Location: The Revere Hotel, Boston
Time: 9:35 a.m. ET
The research is notable because it represents the first analysis of minocycline's impact on inflammatory acne-like lesions in an animal model. Previous studies have focused on P. acnes reduction and acne lesion reduction rather than the P. acnes-related inflammation that may cause or aggravate acne.
"Minocycline is a proven anti-inflammatory drug and commonly used to treat moderate-to-severe acne," said G. Scott Herron, a board-certified dermatologist and fellow of the American Academy of Dermatology. "Minocycline's anti-inflammatory benefits may be even more effective when delivered in a low dose topical formulation as the delivery is both targeted and localized."
BPX-01, BioPharmX's unique topical minocycline gel formulation is the first and only stable hydrophilic (non-oil-based) topical gel with fully solubilized minocycline that can penetrate the skin to deliver the antibiotic to the layer of skin where the acne develops in the pilosebaceous unit.The company's studies are designed to confirm whether BPX-01 will effectively treat acne with lower, and potentially safer, dosages of the antibiotic.
BioPharmX recently initiated a Phase 2b dose-finding study, called the OPAL Trial (tOPicAL minocycline gel), that is a 12-week, multi-center, randomized, double-blind, three-arm, vehicle controlled study and will enroll 225 subjects, aged 9 to 40, with moderate-to-severe inflammatory, non-nodular acne vulgaris.
The American Academy of Dermatology calls acne the "most common skin condition in the United States," affecting 40 million to 50 million Americans. The U.S. market for acne medications is estimated at $10 billion.
About BioPharmX® Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company that seeks to provide products through proprietary platform technologies for prescription, over-the-counter and supplement applications in dermatology. To learn more about BioPharmX, visit www.BioPharmX.com.
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. This press release contains forward-looking statements about the company's expectations, plans, intentions and strategies, including, but not limited to, statements regarding, the effectiveness of topical minocycline on the treatment of acne and inflammation, and the results delivered by the Company's Phase 2b dose-finding study. These forward-looking statements may be identified by words such as "plan", "expect," "anticipate," "believe," or similar expressions that are intended to identify such forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in the company's filings with the Securities and Exchange Commission. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
BioPharmX is a registered trademark of BioPharmX, Inc.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biopharmx-to-present-evidence-that-bpx-01-topical-minocycline-gel-may-reduce-acne-associated-inflammation-300374123.html
SOURCE BioPharmX Corporation